LAG3 and neoplasm: Matsuzaki et al. [9] observed that tumor-infiltrating lymphocytes (TILs) expressing LAG-3 in ovarian cancer decreased the effector function of PD-1+ CD8+ T cells and restored the effector function under co-inhibition of LAG3 and PD-1 in vitro.